Clinical trial
A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer
NCT00426530 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2007
- Completion date
- June 30, 2010
- Enrollment
- 50 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.